hematologic malignancies Mar 8, 2023 Blood-Based MRD Testing Identifies AML Patients at Risk of Relapse After Stem Cell Transplant Mar 7, 2023 Genetic Testing Challenges in Oncology: Karyotype, Germline Clues in Somatic Dx Lost in Translation Mar 7, 2023 Exscientia Partners with Charité Universitätsmedizin Berlin to Advance Treatment Selection Platform Feb 9, 2023 Kura Oncology Begins Phase II Ziftomenib Trial in NPM1-Mutant Acute Myeloid Leukemia Feb 8, 2023 Actinium Pharmaceuticals, NCI Ink Research Agreement on Targeted Radiopharmaceutical Feb 3, 2023 Gracell Biotechnologies to Study CAR T-Cell Therapy in Multiple Myeloma Clinical Trial Feb 3, 2023 Gilead Sciences Reports Q4 Sales Growth for Trodelvy, CAR T-Cell Therapies Premium Jan 27, 2023 Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial Jan 26, 2023 NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients Jan 24, 2023 ImmPact Bio to Begin Phase I/II Trial of Bispecific CAR T-Cell Therapy in Aggressive Lymphoma Dec 28, 2022 Mission Bio, Abiosciences to Develop Analytics For Studying Hematologic Cancers Dec 22, 2022 OneChain Immunotherapeutics to Launch CD1a-Targeting CAR T-Cell Therapy Trial in T-Cell Leukemia Dec 21, 2022 Cedars-Sinai Sets Up New Precision Oncology-Focused Lymphoma Program Dec 19, 2022 Ordaōs, Yatiri Bio Ink Deal to Discover, Develop More Personalized Drugs for AML Dec 15, 2022 Leukemia Patients See Survival Benefit With Integrated Functional Drug, Molecular Testing Approach Premium Dec 15, 2022 Immix Biopharma Forms New Subsidiary, In-Licenses Multiple Myeloma CAR T-Cell Therapy Dec 13, 2022 Amgen to Seek Blincyto Approval in MRD-Negative ALL Following Positive Phase III Results Premium Dec 13, 2022 Gilead's Yescarta Safe and Effective for CNS Lymphoma Patients, Pilot Study Shows Premium Dec 11, 2022 Bristol Myers Squibb, 2seventybio's Abecma Shows Benefit in High-Risk Multiple Myeloma Patients Premium Dec 8, 2022 Daiichi Sankyo Transfers Rights to Market Yescarta in Japan to Gilead Sciences Load More Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
